Return to search

5AM Venture Management hires Bristol-Myers Squibb executive

5AM Venture Management has hired Brian Daniels as a venture partner and Stephen Bonelli as chief financial officer. Daniels was most recently senior vice president in global development and media affairs for Bristol-Myers Squibb, and a member of the company’s senior management team. Bonelli joined from Three Arch Partners, where he was CFO from 2005 to 2014.

Press Release

5AM Venture Management, LLC (5AM) of Menlo Park, CA and Waltham, MA is pleased to announce the addition of Brian F. Daniels, M.D. as a Venture Partner and Stephen J. Bonelli, C.P.A. as Chief Financial Officer.

“We are delighted to announce that Dr. Daniels is joining our team of investment professionals. The depth and breadth of his clinical development experience will add significant value to the firm, as we continue to actively build life science companies,” said Scott Rocklage, Ph.D., Managing Partner. “Brian’s experiences working within large pharmaceutical companies provide meaningful insights that complement our existing team.”

Dr. Daniels has extensive experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutic areas. He most recently was Senior Vice President, Global Development and Medical Affairs for Bristol-Meyers Squibb, and a member of the Senior Management Team, the company’s most senior leadership group. Brian directed the development of innovative medicines, including Apixaban®, Onglyza®, Myalept® and Farxiga® (CV/metabolics), Orencia® and Nulogix® (immunology), Abilify® (neuroscience), Baraclude®, Reyataz®, Daclatasvir® and Asunaprevir® (virology) and Sprycel®, Ixempra®, Yervoy®, elotuzumab and nivolumab (oncology). Dr. Daniels previously held positions directing and conducting clinical research at Merck Research Laboratories and at Genentech.

Dr. Daniels earned his M.D. from Washington University School of Medicine, and holds a M.S. in Metabolism and Nutritional Biochemistry and a B.S. in Biology, each from Massachusetts Institute of Technology. Brian completed residency programs in internal medicine at The New York Hospital of Cornell Medical College in New York, and in rheumatology at the University of California, San Francisco.

Steve Bonelli recently joined 5AM from Three Arch Partners, a $1 billion life sciences venture fund, where he was CFO from 2005-2014. “We are pleased to add Steve to our professional team.” said Andrew Schwab, Managing Partner. “His experience as CFO of a leading life science venture capital firm and CFO of multiple life science companies will add significant value to both the investment and operational sides of our business.”

Prior to Three Arch, Steve had over 20 years of experience as a financial professional, includingten years as senior financial executive in the life sciences industry. He served as CFO of USystems, a breast ultrasound company subsequently sold to GE Healthcare; Align Technology (Nasdaq: ALGN), a dental technology company which he took public in 2001; and General Surgical Innovations a medical technology company, which went public in 1996 and was soldto Tyco International in 1999. Steve previously held a management position with Ernst & Young.

Steve received his B.S. in Business Administration from California Polytechnic State University, San Luis Obispo. He is a Certified Public Accountant in California.

About 5AM Ventures
Founded in 2002, 5AM Ventures actively invests in next-generation life science companies.
The firm is currently investing 5AM Ventures IV, L.P., a $250 million venture capital fund which
closed in 2013. With over $685 million under management, 5AM has invested in 49 earlystage
companies and its successful realizations include Alexza Pharmaceuticals (Nasdaq:
ALXA), DVS Sciences (sold to Fluidigm), Envoy Therapeutics (sold to Takeda), Flexion
Therapeutics (Nasdaq: FLXN), Ilypsa (sold to Amgen), Incline Therapeutics (sold to The
Medicines Company), Marcadia (sold to Roche), Miikana Therapeutics (sold to EntreMed),
Panomics (sold to Affymetrix), Pearl Therapeutics (sold to AstraZeneca), Relypsa (Nasdaq:
RLYP), Semprus (sold to Teleflex) and Synosia Therapeutics (sold to Biotie Therapies). For more
information, please visit